Skip to main content
main-content

13-08-2018 | FDA | News

approvalsWatch

Mogamulizumab-kpkc approved for rare NHL subtypes

medwireNews: A monoclonal antibody agent targeting CC chemokine receptor type 4 may now be used for US patients with relapsed or refractory Sézary syndrome or mycosis fungoides.

The FDA approval follows findings from a clinical trial of 327 patients with these rare non-Hodgkin lymphoma forms who had received at least one prior treatment. Compared with use of vorinostat, patients using mogamulizumab-kpkc had significantly longer progression-free survival.

The agent carries serious warnings for skin toxicity, infection, autoimmune reactions and complications related to later use of allogeneic stem cell transplantation.

By Lynda Williams

medwireNews is an independent medical news service provided by Springer Healthcare. © 2018 Springer Healthcare part of the Springer Nature group

See also:

Related topics

More on this topic

30-11-2017 | Lymphoma | Image

Mycosis fungoides

30-11-2017 | Lymphoma | Image

Sézary syndrome

09-03-2017 | Lymphoma | Case report | Article

Cutaneous T-cell lymphoma

30-11-2017 | Leukemia | Image

Mycosis fungoides